Edition:
United Kingdom

People: Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

46.80CHF
13 Nov 2018
Change (% chg)

CHF-0.58 (-1.22%)
Prev Close
CHF47.38
Open
CHF48.26
Day's High
CHF48.26
Day's Low
CHF46.00
Volume
40,207
Avg. Vol
69,762
52-wk High
CHF81.45
52-wk Low
CHF44.02

Scala, Domenico 

Mr. Domenico Scala has served as Chairman of the Board of Directors of Basilea Pharmaceutica Ltd since April 21, 2016. He is Chairman of the Audit Committee at the Company. Prior to that, he was Vice Chairman of the Board of Directors at the Company from April 9, 2013. Previously, he was Member of the Board of Directors at the Company from April 6, 2011. From 2007 to 2011, Mr. Scala was President and Chief Executive Officer of Nobel Biocare Holding AG and from 2003 to 2007, he was Chief Financial Officer of Syngenta International AG. From 1995 to 2003, he served in various senior leadership positions at Roche Holding AG. Prior to that, he served as Finance Director with Panalpina Italy Spa and Senior Auditor with Nestle SA. Mr. Scala was elected as a Member of the Bank Council of the Basler Kantonalbank in December 2016 (term starting on April 1, 2017). In addition, Mr. Scala has been President of BaselArea, Chairman of the Board of Directors of BAK Basel Economics AG and a Member of the Board of Overseers of Tufts University in Boston, Massachusetts. From May 2012 until May 2016, Mr. Scala was Chairman of the Audit and Compliance Committee of FIFA (Federation Internationale de Football Association). Mr. Scala graduated from the University of Basel with a degree in economics and holds Executive Development degrees from INSEAD and London Business School.

Basic Compensation

Total Annual Compensation, CHF 329,938
Restricted Stock Award, CHF --
Long-Term Incentive Plans, CHF --
All Other, CHF --
Fiscal Year Total, CHF 329,938

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --